Duygu GÜZEL, NURİ YILDIRIM, Ayşegül DİKMEN, Levent AKMAN, Necmettin ÖZDEMİR, Osman ZEKİOĞLU, Zeynep ÖZSARAN, Ulus Ali ŞANLI, Erdem GÖKER, Ayfer HAYDAROĞLU, Mustafa Coşan TEREK, Ahmet Aydın ÖZSARAN

Over kanserinin epidemiyolojisi ve genel sağ kalım özellikleri

Amaç: Ege Üniversitesi Hastanesinde 1992-2017 arası tanı alan ve tedavisi yapılan 1770 over kanserli olgunun epidemiyolojik ve sağ kalım özelliklerini analiz etmek ve sonuçlarını literatürle karşılaştırmaktır. Gereç ve Yöntem: Ege Üniversitesi Kanserle Savaş Araştırma ve Uygulama Merkezi tarafından toplanan over kanseri verileri CANREG özel bilgisayar programına kaydedilmiş, DSÖ ve SEER sistemleri temelinde gruplanarak analizler yapılmıştır. İstatistiksel analizlerde Ki-kare, General Linear Model, Kaplan Meier sağ kalım analizleri uygulanmıştır. Kaplan Meier sağ kalım analizinde Log Rank (Mantel-Cox), Breslow (Generalized Wilcoxon) ve Tarone-Ware istatistikleri kullanılmıştır. İstatistik analizlerde p

Epidemiologic fetaures and survival outcomes of ovarian cancer

Aim: The aim of this study was to analyze the epidemiological and survival characteristics of 1770 ovarian cancer patients diagnosed and treated in Ege University Hospital between 1992 and 2017 and to compare the results with the literature. Materials and Methods: Data recorded to CANREG-4 program in EUH between 1992-2017 by EU Fight Against Cancer Research and Application Center (EUKAM) were grouped according to WHO and SEER systems. For statistical analysis, Chi-square method and general linear modeling and Kaplan-Meier analysis were performed. In Kaplan-Meier analysis, Log Rank (Mantel-Cox), Breslow (Generalized Wilcxon) and Tarone-Ware methods were used. p

PDF

___

1. Siegel, R., et al., Cancer statistics, 2014. CA: a cancer journal for clinicians, 2014. 64 (1): 9-29.

2. Ferlay, J., et al., GLOBOCAN 2012 v1. 0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, France: International agency for research on cancer, 2013. 2016.

3. Şencan, İ. and B. Keskinkılıç, Türkiye kanser istatistikleri. T.C. Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu, 2017.

4. http://seer.cancer.gov/statfacts/html/ovary.html (Accessed on April 24.

5. Weiderpass, E. and J.E. Tyczynski, Epidemiology of patients with ovarian cancer with and without a BRCA1/2 mutation. Molecular diagnosis & therapy, 2015. 19 (6): 351-64.

6. Sopik, V., et al., Why have ovarian cancer mortality rates declined? Part III. Prospects for the future. Gynecologic oncology, 2015. 138 (3): 757-61.

7. Robboy, S.J., Robboy's pathology of the female reproductive tract. 2009: Elsevier Health Sciences.

8. La Vecchia, C., Ovarian cancer: epidemiology and risk factors. European journal of cancer prevention, 2017. 26 (1): 55-62.

9. Webb, P.M. and S.J. Jordan, Epidemiology of epithelial ovarian cancer. Best Practice & Research Clinical Obstetrics & Gynaecology, 2017. 41: 3-14.

10. Permuth-Wey, J. and T.A. Sellers, Epidemiology of ovarian cancer, in Cancer epidemiology. 2009, Springer. p. 413-437.

11. Michels, K.A., et al., Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast, and colorectal cancers. JAMA oncology, 2018. 4 (4):516-21.

12. Whittmore, A.S., et al., Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US casecontrol studies: II. Invasive epithelial ovarian cancers in white women. American journal of epidemiology, 1992. 136 (10):1184-203.

13. Chowdhury, R., et al., Breastfeeding and maternal health outcomes: a systematic review and meta‐analysis. Acta paediatrica, 2015. 104: 96-113.

14. Sieh, W., et al., Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. International journal of epidemiology, 2013. 42 (2): 579-89.

15. Terplan, M., E.J. Smith, and S.M. Temkin, Race in ovarian cancer treatment and survival: a systematic review with meta-analysis. Cancer Causes & Control, 2009. 20 (7): 1139-50.

16. SANTIN, A., et al., SECRETION OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN OVARIAN CANCER. European journal of gynaecological oncology, 1999. 20 (3): 177-81.

17. Merogi, A., et al., Tumor-host interaction: analysis of cytokines, growth factors, and tumor-infiltrating lymphocytes in ovarian carcinomas. Human pathology, 1997. 28 (3): 321-31.

18. Heintz AP, O.F., Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S, Beller U., Carcinoma of the fallopian tube. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:145-60.